RLMD vs URGN
RLMD: Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate. URGN: UroGen Pharma is transforming the treatment of urothelial cancers with its proprietary hydrogel technology that allows for non-surgical, sustained-release drug delivery.
Side-by-side fundamentals
| Metric | RLMD | URGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.00 | $42.06 | |
| Market cap as of 2026-07-23 | $524M | $2.1B | |
| Net margin as of 2026-07-23 | -500.0% | -94.8% | URGN higher |
| Gross margin as of 2026-07-23 | +0.0% | +89.8% | URGN higher |
| Operating margin as of 2026-07-23 | -500.0% | -77.0% | URGN higher |
| ROE as of 2026-07-23 | -71.2% | -204.5% | RLMD higher |
| ROA as of 2026-07-23 | -64.5% | -62.8% | URGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 4.77 | RLMD lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +52.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +19.5% | |
| Beta as of 2026-07-23 | 0.48 | 1.53 | |
| 1-year return as of 2026-07-22 close | +699.4% | +148.0% | RLMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.